KALA Kala Pharmaceuticals Inc.

7.25
+0.02  (+0%)
Previous Close 7.23
Open 7.43
Price To Book 6.09
Market Cap 261,625,342
Shares 36,086,254
Volume 1,421,099
Short Ratio
Av. Daily Volume 604,903
Stock charts supplied by TradingView

NewsSee all news

  1. Kala Pharmaceuticals Announces Completion of Enrollment of STRIDE 3 Trial for EYSUVIS™ (KPI-121 0.25%) for Dry Eye Disease

    –STRIDE 3 Topline Data Targeted in First Quarter of 2020– Kala Pharmaceuticals, Inc. (Kala) (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its

  2. Kala Pharmaceuticals to Present at 38th Annual J.P. Morgan Healthcare Conference

    Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery

  3. Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

    Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2017 Equity Incentive Plan in accordance with

  4. Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

    Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2017 Equity Incentive Plan in accordance with

  5. Kala Pharmaceuticals Reports Third Quarter 2019 Financial Results

    –Conference Call and Webcast Today at 8:00 a.m. ET– Kala Pharmaceuticals, Inc. (Kala) (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

FDA approval announced August 23, 2018.
INVELTYS
Post‑operative inflammation and pain following cataract surgery
Phase 3 data released January 5, 2017 - both primary symptom endpoints met. Primary sign endpoint missed.
INVELTYS - STRIDE 1
Dry eye disease
CRL issued August 8, 2019. NDA to be resubmitted 1H 2020.
KPI‑121 0.25%
Dry eye disease
Phase 3 completion of enrolment announced January 15, 2020 with data due 1Q 2020.
KPI‑121 0.25% STRIDE 3
Dry eye disease

Latest News

  1. Kala Pharmaceuticals Announces Completion of Enrollment of STRIDE 3 Trial for EYSUVIS™ (KPI-121 0.25%) for Dry Eye Disease

    –STRIDE 3 Topline Data Targeted in First Quarter of 2020– Kala Pharmaceuticals, Inc. (Kala) (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its

  2. Kala Pharmaceuticals to Present at 38th Annual J.P. Morgan Healthcare Conference

    Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery

  3. Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

    Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2017 Equity Incentive Plan in accordance with

  4. Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

    Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2017 Equity Incentive Plan in accordance with

  5. Kala Pharmaceuticals Reports Third Quarter 2019 Financial Results

    –Conference Call and Webcast Today at 8:00 a.m. ET– Kala Pharmaceuticals, Inc. (Kala) (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary

  6. Kala Pharmaceuticals to Report Third Quarter 2019 Financial Results and Host Conference Call

    Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery

  7. Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

    Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to two new employees as an inducement award outside the Company's 2017 Equity Incentive Plan in accordance

  8. Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

    Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted a non-statutory stock option to one new employee as an inducement award outside the Company's 2017 Equity Incentive Plan in accordance

  9. Kala Pharmaceuticals to Present at Two Upcoming Investor Conferences in September

    Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery